Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition

This article was originally published in The Rose Sheet

28 Feb 2017
News

Eileen Francis eileen.francis@informa.com

Executive Summary

Prolacta Bioscience developed human milk-based formula fortifier for full-term infants born with conditions that make them vulnerable to nutrition deficiencies. Pending results from research at 12 US hospitals, the product would roll out commercially in 2018.

Already Registered? Sign in to continue reading.

New to HBW Insight? Start a free trial today!

Table
View full table

Topics

Regions
North America

United States

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

United States Dietary Supplements Research and Development Strategies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

RS109104

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

RS109104

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Prolacta Formula Fortifier Starts Trial For Newborns With Rare Heart Condition

News

Executive Summary

Related Content

Updated Infant Formula Regs Raise Quality Control Bar

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert